Reference

Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?

All Rights Reserved. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?. Gibson, Tara Beers; Grothey, Axel (CIG Media Group, LP, Dallas, TX, USA). Clinical Colorectal Cancer, 6(3), 196-201 (English) 2006 CIG Media Group. CODEN: CCCLCF. ISSN: 1533-0028. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The question of continuous vs. intermittent chemotherapy for patients with metastatic colorectal cancer has been an ongoing issue of debate for detg. the optimum duration of treatment. The results from 2 major trials addressing this issue were recently presented at the 2006 Annual Meeting of the American Society of Clin. 61825-94-3 and 97682-44-5 are also in the experiment. Oncol. The OPTIMOX2 trial evaluated the efficacy and safety of oxaliplatin reintroduction after a complete chemotherapy-free interval or maintenance therapy in patients with previously untreated disease. The GISCAD (Italian Group for the Study of Digestive Tract Cancer) study investigated the utility of intermittent vs. continuous irinotecan-based chemotherapy. Both studies demonstrated that chemotherapy can be administered intermittently without affecting the overall efficacy of treatment. .

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Mori, Kiyoshi; Kondo, Tetsuro; Kamiyama, Yukari; Kano, Yasuhiko; Tominaga, Keigo (Department of Thoracic Diseases, Tochigi Cancer Center, Utsunomiya, Tochigi 320, Japan). Cancer Chemotherapy and Pharmacology, 51(5), 403-406 (English) 2003 Springer-Verlag. CODEN: CCPHDZ. ISSN: 0344-5704. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Purpose: Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a b-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea. Methods: Of 44 previously untreated patients with advanced non-small-cell lung cancer randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation. The chemotherapy regimen consisted of a combination of cisplatin and CPT-11. TJ-14 (7.Several substances like 97682-44-5 may be metioned in this study.5 g/day) was administered orally. Results: Of the 41 patients, 39 experienced diarrhea. Compared with the control group, the TJ-14 group showed a significant improvement in diarrhea grades as well as a reduced frequency of diarrhea grades 3 and 4 (one patient vs. ten patients). However, the two groups showed no differences in the frequency of diarrhea or the no. of days the symptoms continued. This study was stopped at an interim evaluation. Conclusion: TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea. .